WINCHESTER, CA–(Marketwire – August 26, 2010) – Minutes after her father — a veteran of WWII — left to fight in the Korean War, Sandi Kriebel was born. “I was raised in a patriotic home. One of my brothers served in Vietnam and the other was in the Navy. We flew the American flag every day,” says Kriebel.

These days Kriebel applies that patriotism by working with hospitalized veterans distributing HHV-provided therapeutic arts & crafts kits at the Baltimore VA Medical Center, a position funded by Help Hospitalized Veterans (HHV). What makes her story touching is the fact that her son, a veteran of the Persian Gulf War, is seriously ill. “There are reminders of the pain he endures every day. I want to make sure all veterans, particularly those in VA hospitals and nursing homes, know they are not forgotten,” she adds.

Kriebel enjoys her work, witnessing the benefits of the craft kits every day. “When I approach a veteran to try something new, the initial reaction is oftentimes reluctance.” With encouragement, however, Kriebel says reluctance gives way to curiosity, then finally — willingness to try a project. “I’ve seen fear replaced with hope and despair replaced with enjoyment. As veterans work on their craft kits, levels of confidence and self-esteem increase,” says Kriebel.

In addition, a breakthrough moment was observed by a therapist on the mental health unit who was having difficulty getting patients to open up during group sessions. The therapist noticed that, while working on HHV’s leather craft items, a couple of the patients were talking to each other. Therapists decided to incorporate arts & crafts into regular group therapy. “You’d be amazed at the positive difference craft kits have made,” Kriebel added.

Since 1971, HHV has donated over 25 million therapeutic arts & crafts kits to our nation’s VA and military hospitals at no charge. For more information on HHV’s variety of programs and services — all of which are made possible through the generous support of donors throughout the United States — visit www.hhv.org.

Documents and/or Photos available for this release:
PDF_of_release

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 268310

FRIENDSWOOD, TX–(Marketwire – August 26, 2010) –  TrinityCare Senior Living, Inc. (OTCBB: TCSR), which develops, manages and owns faith-based senior living facilities, today announced the execution of an agreement with SeaBridge Freight, Inc., a Delaware company, which provides container-on-barge transport service between Port Brownsville, Texas and Tampa Bay, Florida.

“This agreement will create a change in focus for our public company, and a change we believe will be beneficial to our shareholders,” stated Donald W. Sapaugh, Chairman and Chief Executive Officer of TrinityCare Senior Living, Inc. “SeaBridge Freight, is a leader as a ‘Marine Highway,’ with revenues increasing each quarter this year. The company has excellent leadership and is poised to expand rapidly over the next year.”

This reorganization agreement has been approved by a majority of the shareholders of both companies, and further information will be available shortly.

About TrinityCare Senior Living, Inc.

TrinityCare Senior Living (“TrinityCare”) develops, owns, and manages quality senior living facilities that focus on enriching the faith of the residents and providing state-of-the-art independent living, assisted living, memory care and adult day care services in a single location. The Company partners with local churches and developers for each facility and offers a wide range of both community and personal services to residents. TrinityCare is a rapidly growing company with three successful facilities currently operating in Texas and Tennessee. Near-term expansion plans target the Southeastern part of the United States. For more information please visit www.trinitycare.com.

TrinityCare is headquartered in Friendswood, Texas (Houston metropolitan area) and its common stock trades on the OTC Bulletin Board under the symbol “TCSR.”

Forward-Looking Statements

The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements related to the future financial performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful execution of growth strategies, product development and acceptance, the impact of competitive services and pricing, general economic conditions, and other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission.

IRVING, TX–(Marketwire – August 26, 2010) –  Seven hospitals in North Carolina, all members of VHA Inc., the national health care network, formed the Southern Atlantic Health Care Alliance, known as SAHA, purchasing coalition in 2007. Within the past two years, they have saved $2.8 million by aggregating their purchasing volume and achieving greater savings than they could have realized individually, while retaining their ability to make independent decisions about product purchases as hospitals adopt tactics that help them do more with reduced resources. 

“Almost daily, our member hospitals tell us that current conditions are forcing them to stretch their budgets without impinging upon patient care,” said Scott Downing, executive vice president of Supply Chain Management at VHA. “Purchasing coalitions create opportunities for savings on clinical commodities that hospitals use every day as well as more specialized products, resulting in significant savings while fostering peer-to-peer interaction and knowledge sharing.”

Working with VHA to focus on supply chain improvement activities, SAHA purchasing coalition acts as a single entity to drive savings and supply chain efficiency that reduce supply expenses. On average, members of VHA Supply Networks save 8% to 12% annually through network contracts.

Demonstrating the benefits of aggregation, collaboration, commitment and teamwork, SAHA members anticipate significant savings while preserving patient safety. For example, they created a prototype, with member-approved new features for some existing patient footwear. Because members agreed to aggregate their purchasing volumes and the supplier, Encompass, agreed to make the changes and lower the cost, this standardization initiative will reduce costs and decrease the number of inventory stock keeping units, or SKUs, for hospitals that discontinue their use of hard-soled slippers. 

“The Moses Cone Health System values the SAHA membership because we’ve realized more than $500,000 in savings since joining the network,” says Susan Aquino-Smith, SAHA’s chairman of the Joint Implementation Team and Contract Administrator for The Moses Cone Health System in Greensboro, NC. “We are working on several initiatives and believe that these savings will grow as SAHA continues to mature.” 

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 28,000+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

IRVINE, CA–(Marketwire – August 26, 2010) –  A partnership between the Cystinosis Research Foundation and the Cystinosis Foundation along with a collaboration of 12 advocate foundations from around the world has launched the first global cystinosis patient registry. The registry’s goal is to connect patients with researchers and others developing potential new treatments and a cure for the metabolic and fatal disorder that afflicts about 2,000 persons, mostly children, worldwide.

The purpose of the Cure Cystinosis International Registry is to identify people with cystinosis worldwide and collect their medical histories and information. This information will allow clinicians, researchers and pharmaceutical companies to accelerate novel treatments and a cure for cystinosis.

“The cystinosis community has experienced exciting scientific advancements to treat and cure cystinosis. Currently there is a proliferation of research activity, breakthroughs and hope. The CCIR is a central hub of information and will be used as a resource for the research community and could prove vital to advances in the care and treatment for those with cystinosis,” said Nancy Stack, President of the Cystinosis Research Foundation.

The CCIR is the only registry created specifically for individuals with cystinosis and will contain current information regarding cystinosis clinical trials and studies. All patient information is de-identified (anonymous) and held in a secure data base accessible only by the CCIR curator. Information that could identify participants and their family members will not be shared without their expressed written approval. Participants will also be able to view aggregate data allowing them to view how they fit within the larger cystinosis community.

The registry was formed following discussions which began in 2009 among leaders in the cystinosis community who saw the need to establish a new and comprehensive resource to connect and serve the needs of the entire cystinosis community. The CCIR’s organizers come from family foundations around the world and the cystinosis academic and scientific communities. These groups are focused on the need to accelerate the research process in the quest to find the cure for cystinosis.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of one of the compartments of the cell. Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

CCIR officials say recruitment for clinical trials can be a lengthy process, especially for a rare disease like cystinosis. Participation in this registry will help speed up the recruitment process and facilitate and expedite clinical trials, officials said.

Plans are to offer the website in French, Italian and Spanish following the launch.

One of the major features of the registry is a professional/researcher portal that will allow the scientific and pharmaceutical communities to request access to de-identified patient information. Those seeking patient information have to meet stringent requirements governing patient medical data, including patient approval. Each request will be reviewed by the CCIR curator and operations board.

Twelve other cystinosis foundations have joined as advocates of the CCIR. They are: the Cystinosis Awareness & Research Effort in Canada; the Australian Cystinosis Support Group; Cystinosis France, Cystinosis Foundation UK, Cystinosis Ireland, The Cystinosis Foundation, New Jersey Chapter; Cystinosis Support Group South Africa, 24 Hours for Hank; Hope For Holt; Jenna & Patrick’s Foundation Of Hope, Joshua’s Journey of Hope and Tina’s Hope for a Cure.

For more information about Cure Cystinosis International Registry and the Cystinosis Research Foundation of Irvine, Calif., contact Zoe Solsby at (949) 223-7610 or visit www.cystinosisregistry.org or www.cystinosisresearch.org.

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – August 26, 2010) –  This year, thousands of people in communities across the country will join the movement to Stop Diabetes® by participating in the American Diabetes Association’s Step Out: Walk to Fight Diabetes event. Step Out is a fundraising walk that takes place in more than 140 cities to raise awareness about diabetes and to raise much needed funds to help change the future of this growing epidemic that is taking a physical, emotional and financial toll on our country.

Step Out: Walk to Fight Diabetes is a family event for those who want to become involved in the community and help change the future of diabetes. Participants can walk as an individual or create a team and walk with friends, family, and co-workers.

Do you want to show what it is like to live with diabetes? The American Diabetes Association is also looking for Red Striders. A Red Strider is a person with diabetes who has a passion to stop diabetes and is willing to put a face on this disease by helping others understand what it takes to live with — and fight — this serious disease.

“On the day of Step Out, it is very important to recognize all of the people with diabetes,” said Christine Schaeberle, founder of one of the first Red Strider programs in Colorado. “By wearing red hats that signify that we are living with diabetes, we are able to recognize people with diabetes who are taking steps to stop diabetes.”

Join Christine and other Red Striders in the movement to Stop Diabetes as they ‘Step Out’ this year wearing their Red Strider red hats.

“The Red Strider program really opened my eyes to the fact that I am not alone and I am joined by so many other people who are living with diabetes. For people who participate in Step Out and don’t have diabetes themselves, this is a way for them to see the many faces of diabetes and reinforce the fact that diabetes affects people of all ages and ethnicities. These are the faces that encourage me to walk, and I am inspired to do all that I can do to fight this disease each and every day. I am encouraged to share my story with the hope that other people will join me in raising money to stop diabetes,” added Schaeberle.

Today, there are nearly 24 million children and adults in the United States who have diabetes. While nearly 18 million people have been diagnosed, there are 5.7 million people who don’t even know that they have the disease. If present trends continue, 1 in 3 Americans, and 1 in 2 minorities, will face a future with diabetes. To date, the American Diabetes Association has raised and donated more than $450 million for diabetes research.

National sponsors of Step Out: Walk to Fight Diabetes include Equal® Sweetener, Pure Via™ All Natural Zero Calorie Sweetener, Cary’s® Sugar Free Syrup and Walmart. Be a part of the cure and start raising money today. To register, volunteer or find out more information, please visit diabetes.org/stepout or call 1-888-DIABETES. Together we can stop diabetes. One step at a time.

About the American Diabetes Association
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

MUNDELEIN, IL–(Marketwire – August 26, 2010) –  Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost management prime vendor agreement with Northeast Alabama Regional Medical Center based in Anniston, Alabama. The five-year agreement is anticipated to deliver significant savings for the hospital over the term of the contract.

Under the agreement, Northeast Alabama Regional Medical Center will receive a broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages. The hospital can also leverage other Medline clinical and educational evidence-based programs that were carefully designed to affect clinical outcomes, drive cost savings and improve patient satisfaction. 

Northeast Alabama Regional Medical Center will benefit from significant cost savings through the delivery of Medline manufactured products shipped directly from Medline’s distribution center located in Atlanta, GA.

Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About East Jefferson General Hospital 
East Jefferson General has grown over the past three decades to become a medical landmark with the addition of medical office buildings, the Yenni Pavilion for outpatient cancer treatment, and the Domino Pavilion, which houses Same Day Surgery, outpatient laboratory and outpatient radiology services. Most recently, the Wellness Center, a 38,000 square foot, state-of-the-art fitness facility, was added to the hospital’s main campus.

East Jefferson General Hospital has grown with the East Bank community, offering the clinical expertise and cutting edge technology our community expects and deserves. Today, the hospital remains publicly owned and not-for-profit. It is a service district hospital governed by a 10-member volunteer Board of Directors appointed by the Jefferson Parish Council and the Parish President. The hospital is accredited by the Joint Commission on Accreditation of Healthcare Organizations. In 2002, East Jefferson General became Louisiana’s first Nurse Magnet Hospital. This honor is bestowed by the American Nurses Credentialing Center on select hospitals that demonstrate excellence in patient care and provide a superior environment for professional nurses.

About Medline Industries, Inc.
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies and other markets. Headquartered in Mundelein, IL, Medline has more than 800 dedicated sales representatives nationwide to support its broad product line and cost management services. 

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 250 major hospitals and health care systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

Medline has a growing network of 34 distribution centers around the country, as well as an expanding, dedicated transportation fleet with over 180 vehicles in a variety of sizes to fit customers’ specific delivery needs. The fleet is equipped with the latest navigation devices for enhanced order tracking and communication. For more information on Medline, visit our Web site, www.medline.com.

SAN FRANCISCO, CA–(Marketwire – August 26, 2010) –  As children return to school, parents naturally consider how to help their children learn and succeed. Good vision and eye health are key to students’ ability to do well in the classroom, on the playground, in sports, and when studying at home. September is Children’s Eye Health and Safety month, and the American Academy of Ophthalmology encourages families to make sure students receive vision screening and learn eye health and safety practices. Also, it’s important for parents of children with learning disabilities to know how vision does — and does not — play a role.

Mary Lou Collins, M.D., a pediatric ophthalmologist in the Baltimore, Maryland area, said Quinn Kirby’s story illustrates how screening can make a big difference to a child’s future. Quinn is a bright, lively little girl whom Dr. Collins initially saw at age four.

The first hint that Quinn might have a vision problem was picked up in her pediatrician’s office. In a preliminary screening Quinn couldn’t name the pictures or letters — and she expressed a lot of frustration about that, since she knew her alphabet. Dr. Doran and Quinn’s mom, Kris, agreed on sending her to Dr. Collins for a comprehensive exam.

“We found that Quinn’s vision was 20/30 in her right eye and 8/200 in the left, compared with 20/20 normal vision,” Dr. Collins said. “Quinn’s stronger eye was doing most of the work, and her other eye was becoming weaker as a result, a condition called amblyopia. Also, Quinn’s weaker eye was slightly turned inward (one variation of a condition called strabismus), but this was too subtle to be noticed, except in an exam.”

Her parents take excellent care of their kids’ health, and so were stunned by the news. Dr. Collins told them not to blame themselves as such vision problems are nearly impossible to detect — especially in young children — except through vision screening by a school nurse, pediatrician or other qualified health provider. When a potential problem is revealed, a comprehensive eye exam by an ophthalmologist is the best way to determine whether vision correction or other treatment is needed.

Parents may have questions on how the eyes and vision interact with learning disabilities in children. These disabilities result from the brain’s misinterpretation of images received and relayed by the eyes, rather than from structural or functional eye problems. That’s why learning disabilities are not treatable by eye exercises or vision therapy. If disabilities are suspected, students need testing, followed as appropriate by in-depth neurological exams and treatment. And whether or not learning disabilities are suspected, all students need vision screening to check eye health and visual acuity.

Kris, who teaches third grade, said some of her students’ learning struggles might have been avoided if they had vision screening and treatment when they entered kindergarten, or as soon as vision or learning problems were suspected.

“I’d encourage all parents to make sure your children get screened at school, at your pediatrician’s office, or through another health service,” Kris said. “My husband and I are grateful that Quinn’s problem was discovered and treated early. She’s now almost 5 1/2, with 20/25 vision in her right eye and 20/30 in the left. She loves being able to do what ever her big brother does and enjoys reading with us.”

Her treatment included glasses — at first with very thick lenses — but Kris says Quinn liked choosing the pink and purple frames and didn’t mind wearing them. The eye patch treatment was a different story: after three months of persuasion, Quinn agreed to wear the patch over her stronger eye for about eight hours daily so that her weaker eye took on the work of seeing and developed more normally. “Actually, she insisted all of us wear patches along with her. Quinn and my husband in their daisy eye patches were famous at our local market!” Kris added.

For more on children’s eye health and safety at home, school and during sports, visit:
http://www.geteyesmart.org/eyesmart/resources/children/index.cfm

About the American Academy of Ophthalmology
American Academy Ophthalmology is the world’s largest association of eye physicians and surgeons — Eye M.D.s — with more than 29,000 members worldwide. Eye health care is provided by the three “O’s” — opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy’s Web site at www.aao.org.

ROSWELL, GA–(Marketwire – August 26, 2010) –  Economic globalization brings increased international business travel, and as a result, greater exposure to communicable illnesses.

The H1N1 pandemic that began last year in Mexico forced many companies to face this reality, and new threats are emerging continuously, with illnesses such as Yellow Fever, Hepatitis A & B, Malaria and Japanese Encephalitis confronting today’s business travelers.

The key to mitigating these threats is Passport Health (www.passporthealthusa.com), a leading provider of travel health information and immunizations for international travelers, major corporations, universities and other international organizations, and a Charter Sponsor of the recently launched PREACTION EMERGENCY RESPONSE ALLIANCE™.

The PREACTION ALLIANCE™ (www.preaction.com) is a first-of-its-type private network offering business continuity and disaster-response capabilities through a low monthly-fee, membership-based organization. By becoming a Charter Sponsor, Passport Health has provided its network of franchisees — which comprise more than 170 locations nationwide — access to a free annual membership in the PREACTION ALLIANCE. Thereafter, Member benefits can be retained for less than $1 a day.

“Passport Health is committed to the health and well-being of all employees and our Vaccine Specialists are mission-ready to respond quickly to PREACTION ALLIANCE Members’ needs, including disaster relief and emergency preparedness,” said Fran Lessans, Passport Health CEO.

“The question about pandemics is not if, but when they will happen. We just saw the impact that the H1N1 pandemic had on corporate productivity,” Lessans added. “All businesses should have a pandemic plan in place and have a plan to deliver antivirals to employees if necessary. Passport Health’s presence in the PREACTION ALLIANCE assures that vaccines are available to Members and that they can be administered in short notice.”

The PREACTION ALLIANCE was developed by Firestorm® (www.firestorm.com), a national leader in crisis management, threat assessment/risk analysis, and business continuity. Other Charter Sponsors include W.W. Grainger Inc., the leading supplier of maintenance, repair and operations products.

“The ability to travel the world is one of the great aspects of modern society. Unfortunately, introduction to unusual places, people, and cuisine is often accompanied by exposure to disease threats for which your body is ill-prepared,” said Dr. Don Donahue, Firestorm’s Director of Healthcare Response. “Overseas trips — for business or pleasure — should be preceded by a travel medicine consultation. Vaccination and prophylaxis are critical requirements in many corners of the globe.”

BAY HARBOR, FL–(Marketwire – August 26, 2010) –  SmartMetric, Inc. (OTCBB: SMME) announced today that its fingerprint activated Biometric Data Card can be now used to provide the highest level of both security and portability for a person’s medical history and full medical records.

Colin Hendrick, President and CEO, stated, “Once again our research and development team has pioneered another exciting breakthrough in our Biometric Data Card. We believe that nothing like this exists anywhere in the world today. We are currently in negotiations with several worldwide corporate entities regarding the rollout and commercialization of our breakthrough products. We will be updating our shareholders as soon as possible on the status of these talks, as well as our previously announced legal actions against Visa and MasterCard.”

Unlike other portable solutions, the SmartMetric Data Card can store Gigabytes of medical information including full EKGs, complete CT and MRI digital images, and similar data making up an individual person’s complete medical records. Storage of digital images, in particular, requires significant digital storage capacities. Unlike other systems that are severely limited in the amount of digital data that can be held in a portable solution, the SmartMetric Data Card is in fact a powerful digital computer with significant memory capacity sitting inside a Data Card the size of a standard Health Insurance Card. Most importantly, the SmartMetric solution provides the highest level of portable security for the patients information in that it can only be accessed after the patient touches the surface sensor on the Health Card triggering the Card to scan the persons fingerprint and matching it with their fingerprint pre-stored inside the card. Only after a finger print verification internally in the card is the data able to be accessed or viewed by a Doctor, Hospital or even an EMT’s computer.

About SmartMetric, Inc.

SmartMetric, Inc. has developed a portable biometric identity and transaction card capable of storing a wide variety of personal information while protecting you against identity theft and fraud. It is one of the most advanced portable identity authentication solutions in the world today. The card contains a biometric fingerprint scanner and reader which only you can unlock and is smaller and thinner than a credit card. The SmartMetric card is ideal for a wide range of consumers, including Personal, Government and Corporate.

For more information please visit us at www.smartmetric.com

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – August 26, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today target market details for the domestic and international commercialization of its Onko-Sure® in vitro diagnostic (IVD) cancer test. 

RPC received USFDA for its Onko-Sure® IVD cancer test approximately 24 months ago, which marked the point at which RPC could begin commercialization. Since that time a considerable amount of work has gone into creating a domestic & international distribution network, plus the highly effort of validating RPC’s USFDA approved Onko-Sure® test kits with oncologists, gastroenterologist and lab directors. RPC has added various needed validation tools that include the first edition of RPC’s 2010 Onko-Sure® Reference Guide for physicians, oncologists, clinicians, consumers and patients, (“ODR”) designed to significantly gain sales traction for Onko-Sure® in North America and other international markets. The Company is also working on additional clinical trials and inclusion in industry publications to determine the standard of care for cancer diagnosis and targeting additional validation tools, which are anticipated to be in place by year-end. The Company is now in a position to begin making significant headway in commercializing Onko-Sure® in target market.

According to Mr. Douglas MacLellan, Chairman and CEO of RPC, “RPC has focused 18 months of dedicated, diligent work related to product validation, and we expect the Company will demonstrate significantly improved sales results during the second half of FY2010. Given the timing of our US FDA approval and commercialization work, we are akin to a start-up Company. That said, we expect meaningful sales to begin over the next two quarters. We understand there is tremendous market pressure and encourage the investing community to look to the long-term success of RPC, especially given the current economic environment and the very competitive and sophisticated market we are operating in.”

FY2010/ FY2011 Onko-Sure® Commercialization Plan
As RPC executes its domestic and international Onko-Sure® sales plan, the Company is focusing on 4 key target markets, that include:

• US FDA approved use and sales of Onko-Sure® as a CRC Monitoring Test in the U.S. & eventually Canada;
• US FDA approved use and sales of Onko-Sure® as a CRC Monitoring Test in various international markets;
• Use and sales of Onko-Sure® as a general cancer screening test (predominately outside the US, currently in Taiwan and Korea); and,
• Health Canada approved use and sales of Onko-Sure® as a lung cancer screening and monitoring test.

Target Market Segment Details:

• US FDA approved use as a CRC Monitoring Test Market in the US & Canada: This market represents a US$200 million per year market at the wholesale level, and is growing at a 10% annual growth rate. The competing test for Onko-Sure® is the Carcinoembryonic Antigen (CEA) — a test that typically only identifies cancer its latest stages when the probability of treating the disease is lowest. Onko-Sure® has been clinically shown to identify cancer in its earliest stages, and these studies also indicate Onko-Sure® to be a superior test to CEA. To capitalize on this, we are implementing an aggressive commercialization strategy in the US specifically targeted towards physicians, oncologists, clinicians, consumers, patients and reference labs that show demand for the test.

• US FDA Approved use as a CRC Monitoring Test in International Markets: This market represents a US$250 million per year market at the wholesale level, and is also growing at a 10% annual growth rate. We expect sales of Onko-Sure® in North America will create new market share in the International CRC monitoring market by FY2011.

• Government-backed General Cancer Screening Test (predominately outside the US): Government backed general cancer screening represents a potential US$1 billion per year market that is currently in its infancy. International recognition and demand for government-backed general cancer screening has only just begun. U.S. adoption of government back general cancer screening for high risk populations is expected to be commonplace by 2015. Based on RPC market analysis, we anticipate driving solid adoption and sales of Onko-Sure® in high risk populations specifically in India and Colombia by the fourth quarter 2010, and Brazil by the second quarter of 2011. We are actively targeting other countries and expect sales to ramp as RPC’s initial commercialization program in the above markets demonstrates results. Additionally, through our US-based CLIA lab partner, we have initiated product sales for Onko-Sure® that is being used as a general cancer screen in the US and Canada and we are selling Onko-Sure® as a general cancer screen in Korea and Taiwan. In order for RPC to gain up to US$1 billion in Onko-Sure sales from government-backed general cancer screening initiatives (“GCSI”), which would be focused on “patients with a high risk of developing cancer,” RPC will need to sell approximately 1,488,095 kits annually.

• Health Canada Approved use as a Lung Cancer Screening & Monitoring Test: This represents a US$50 million per year market, also currently in an infancy stage. More Canadians are diagnosed with lung cancer than any other cancer type, with mortality from lung cancer higher than breast, colorectal and prostate cancer combined. In 2010 alone, 1 in 12 Canadians are expected to develop lung cancer. Smoking causes most lung cancers. That said, approximately 50% of patients diagnosed have never smoked (15%) or are former smokers (35%). Most lung cancers are diagnosed in late stages, due in part to lack of effective screening procedures, this is a primary factor that leads us to believe Onko-Sure® will become an important and high demand test for cancer screening. Lung cancer patients and their family members are often stigmatized by a widespread prejudice about smoking, and many feel isolated and hesitant to tell others about their diagnosis. Lung cancer receives little public or media attention. This is due, in part, to a small community of survivors to bring a voice and attention to lung cancer issues. We are seeking Canadian government support for a lung cancer screening program to high risk segments of the population.

Global Cancer Statistics & Onko-Sure®
The latest World Health Organization (“WHO”) statistics indicate there are approximately 7.4 million cancer deaths worldwide annually. RPC’s goal is to test approximately 70 million “high risk factor” patients per year with the goal of identifying cancer in approximately 10% of this high risk factor population. According to the WHO, the annual global cost for cancer is approximately US$1 Trillion. By implementing GCSI, and catching early stage cancer, the savings with a low cost test such as Onko-Sure™ could be at least 30% or approximately US$330 billion per year, to government health agencies.

For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of in-vitro diagnostic products.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

References:

• Lung Cancer Canada, lungcancercanada.ca.
• World Health Organization (WHO) Cancer Fact Sheet No. 297, February 2009
• “Cancer costs the world nearly $1 trillion”, By Aaron Smith, CNNMoney.com staff writer, August 17, 2010.

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – August 26, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) is a sponsor of The Gulf is Back,  a one-hour TV special on the CW Network airing this Friday, August 27, 2010, at 8:00 p.m. ET. The Company believes the sponsorship of the special tribute, hosted by David Hasselhoff and featuring musical performances by Lonestar, Ricky Skaggs, Taylor Hicks and Brian McKnight, will help call attention to the importance of having a MyMedicalRecords Personal Health Record account (www.mmrvideos.com) or MyEsafeDepositBox online safe (www.myesafevideos.com) in the event of a disaster or emergency at home or anywhere in the world.

Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer, said, “We are proud to be a sponsor of Associated Television International’s network television special The Gulf is Back. People experiencing a personal or business loss need access to the important documents necessary to rebuild their lives. Our products offer the reliability and resiliency needed to recover more quickly from any emergency or disaster. With MyMedicalRecords, individuals and families can have direct access to their most important documents, including insurance policies, deeds of trust, wills, birth certificates and advance directives in addition to their medical records. Everything is located in one secure, convenient location accessible from any Internet device anywhere in the world.”

Viewers responding to the MyMedicalRecords TV spots on The Gulf is Back will be greeted with the same onscreen technology used for the Daytime Emmy Awards last June. However, in addition to fulfilling requests for information, consumers who sign up for a free trial account can participate in the MMRGlobal $25 cash refund program applied to the viewer’s next check-up or doctor visit.

MMRGlobal’s advertising campaigns can be previewed at www.mmrontv.com. 

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, television programming changes, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – August 26, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that abstracts of three studies involving its PD2i^® nonlinear algorithm have been accepted for presentation during the Poster Session of the 2010 Heart-Brain Summit. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

“We’re honored to have three abstracts selected for presentation before this prestigious group, especially during the distinguished Poster Session. We believe the results achieved by the PD2i^® in each of these studies suggest the prospect of incorporating the PD2i^® nonlinear algorithm into a noninvasive diagnostic that will significantly contribute to the identification and treatment of at-risk patients. We hope that having the opportunity to share these results with those active in the field of heart-brain medicine worldwide will further opportunities to advance study of the PD2i^® as a noninvasive diagnostic to identify at-risk populations and further our commercialization efforts for the PD2i^®,” stated Mr. Fater.

Dr. James E. Skinner, Vicor Vice President and Director of Grant Research, will present the following abstracts at the 2010 Heart-Brain Summit, which will be held at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, September 23-24. The Poster Session is on September 23, from 5:00 to 7:00pm.

Short-Term Heart Rate Complexity Determined by the PD2i^® Algorithm is Reduced in Patients with Type 1 Diabetes Melitus — The objective of this study was to test the ability of PD2i^® to discriminate between young DM patients without neuropathy and age- and gender-matched controls. Seventeen DM patients with known autonomic dysfunction and 17 age- and gender-matched controls were studied. The same R-R interval data (3,200 heartbeats per subject) were analyzed (blinded) to determine the PD2i^® values. The study revealed that the PD2i^® was able to detect ANS dysfunction with p = 0.0006.

Prognostic Significance of PD2i^® in Heart Failure Patients — The goal of this effort was to determine the PD2i^®‘s ability to predict cardiac events in chronic heart failure patients. The study population was a group of chronic heart failure patients, who had been studied for 44 months, on average, with total mortality as primary endpoint and cardiac mortality, sudden cardiac death, and heart failure death as secondary endpoints. The PD2i^® was computed based on 20-minute supine high-resolution Holter recording and was categorized as positive (PD2i® less than or equal to 1.4) or negative (pD2i® greater than 1.4) based on pre-specified criteria. Of the 651 chronic heart failure patients studied, 537 had successful PD2i^® analyses resulting in 144 (27%) patients showing positive results and 393 (73%) negative results. After adjustment for clinical covariates PD2i^®, was found predictive for total mortality (HR=1.55; p=0.026). Predictive value of PD2i^® was observed in heart failure patients with left ventricular ejection fraction less than or equal to 35% (HR=1.95; p=0.004) whereas not in patients with greater than 35% (HR=0.87; p=0.716); p for interaction 0.072. Further analyses revealed that among patients with ejection fraction less than or equal to 35%, PD2i^® was also predictive for cardiac death and for heart failure death.

Mild Hypovolemia and PD2i^® — The goal of this pilot study was to test the ability of the PD2i^® to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. Study subjects were volunteers who presented for a standard single unit whole blood donation. A 15-minute ECG recording was made pre-donation and the recording was then continued during the donation period and a rest afterwards. Eighteen subjects participated with a mean age of 48+/-18 years. Three were on beta blockers, 2 on antidepressants, and 1 had diabetes. At baseline the minimum PD2i^® had a mean of 2.6+/-0.8 dimensions, whereas after donation it fell to 1.8+/-0.5 dimensions (p=0.0011). The minimum PD2i^® was found to be a sensitive metric for the detection of mild blood loss, as seen in the controlled environment of donation of a whole unit of blood. Thus, PD2i^® may serve as a marker for mild hemorrhage in hospital (e.g., surgery) and trauma environments. In addition, given PD2i^®‘s association with autonomic activity, these results suggest significant sympathetic activation with even standard blood donation, suggesting that PD2i^® can be used to track a patient’s autonomic response to insult.

The Heart-Brain Summit, now in its fifth year, is the annual event of The Society for Heart Brain Medicine. More than 200 physicians, researchers, scientists, and industry professionals from around the world attended the 4^th Annual Heart-Brain Summit in 2009.

The Society for Heart Brain Medicine was officially established as a 501(c) (3) organization in June of 2008, with the purpose of:

• educating clinicians and scientists about the physiology, pathophysiology, and medical aspects of heart-brain interactions;
• educating the public about these aspects; and
• promoting and fostering research into heart-brain relationships.

The Society for Heart-Brain Medicine provides a forum for researchers and clinicians from different disciplines, both clinical and laboratory, to present, discuss, and evaluate data, and promotes the study of heart-brain medicine as a discipline in its own right. Additional information about the Society for Heart-Brain Medicine is available at www.heartbrain.org.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Click here to see all recent news from this company

BUENA PARK, CA–(Marketwire – August 26, 2010) –  SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that it has posted a 1,000 percent year-over-year increase in revenue for the second quarter ending June 30, 2010. Due to successive record quarters and the company’s unprecedented corporate revenue growth the Company expects continued consumer adoption of its private label generic pharmaceutical products. Revenues for the three months ended June 30, 2010 increased over 1,000% to $339,545 compared to $33,599 in the second quarter of 2009. Revenue growth was fueled by expansion of current and new clients and from pilot distribution projects to full production deployments.

Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc., stated, “Our ability to generate record revenue growth and accelerated consumer adoption rates for our generic pharmaceutical products is a direct reflection of our sales and marketing team’s dedication. We continue to demonstrate our ability to penetrate and lead in our chosen emerging markets. Most significantly, SOHM has grown and matured its generic drug manufacturing operations allowing for the scalability of resources and product production necessary to support a growing worldwide customer base.”

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

HOUSTON, TX–(Marketwire – August 25, 2010) –  Over the next three days, the Discovery Channel will begin airing a special episode of Health Heroes focused on dental innovations, including a segment on clear aligner therapy. The episode educates viewers about clear aligner therapy, a popular teeth-straightening alternative to metal braces, and also explores how orthodontic manufacturers such as ClearCorrect are making the procedure simpler and more affordable to the public. 

The episode premieres on both the East and West Coast at 7 am on Thursday, August 26, 2010 on the Discover Channel. It will re-air on Dish Network Channel 225 on Friday, August 27, 2010 at 10 pm EDT and on the Discovery Channel via DirectTV on Saturday, August 28, 2010 at 10 pm EDT.

Clear aligner therapy is an orthodontic treatment involving a series of clear, removable aligners that gradually move teeth to improve aesthetics and bite function. The technique, often referred to as “invisible braces,” is becoming increasingly popular with the public and a key growth area for dentists looking to add services.

The Health Heroes episode features dental industry innovators, including ClearCorrect founder Willis Pumphrey, DDS, and how he, along with input from other dentists, worked to create a more patient and doctor-friendly alternative to more costly clear aligner choices on the market.

In the clear aligner process, ClearCorrect receives the patient’s records from their general dentist or orthodontist and creates exact 3D models of the teeth. Working with a doctor, ClearCorrect then maps out a complete treatment plan of gradual adjustment, then manufacturers and delivers the clear aligners used in the procedure. 

For doctors interested in learning more about clear aligner therapy, ClearCorrect will be at two upcoming dental conventions. It will be at the California Dental Association (CDA) convention in San Francisco, CA on September 9-11, 2010 at Booth # 736 and at the American Dental Association (ADA) convention in Orlando, FL on October 9-11, 2010 at Booth #1244.

For more info, call 888-331-3323 toll free; visit www.clearcorrect.com; or write to ClearCorrect, Inc. at 5200 Mitchelldale St., Suite F-26, Houston TX 77092.

NASHVILLE, TN–(Marketwire – August 25, 2010) – Vanguard Health Systems, Inc. (Vanguard)
today announced results for the fourth quarter and fiscal year ended June
30, 2010.

Total revenues for the quarter ended June 30, 2010 were $858.4 million, an
increase of $31.9 million or 3.9% from the prior year quarter. Patient
service revenues increased $17.4 million from the prior year quarter.
Health plan premium revenues increased $14.5 million from the prior year
quarter. The increase in patient service revenues was attributable to a
3.3% increase in adjusted discharges offset by a 0.2% decrease in patient
revenue per adjusted discharge during the current year quarter compared to
the prior year quarter. Absent the implementation of an insured discount
policy in our Phoenix and San Antonio hospitals effective July 1, 2009,
similar to the program implemented in our two Illinois hospitals on April
1, 2009, and a change to the Medicaid pending policy at all of our
hospitals, patient revenue per adjusted discharge would have increased 3.2%
during the current year quarter compared to the prior year quarter. The
increase in health plan premium revenues was primarily attributable to a
17.1% increase in average membership in Phoenix Health Plan (PHP) during
the current year quarter compared to the prior year quarter. Economic
conditions in Arizona continue to increase the number of individuals
eligible for coverage under the Arizona Health Care Cost Containment System
(AHCCCS) and thus expand PHP’s membership.

Vanguard reported income from continuing operations of $3.4 million for the
current year quarter compared to $2.1 million during the prior year
quarter. During the current year quarter, Vanguard’s net income
attributable to Vanguard Health Systems, Inc. stockholders was $2.8 million
compared to $1.8 million during the prior year quarter. Many quarter over
quarter comparisons of individual cost and expense items, particularly for
health plan claims expense and the provision for doubtful accounts, as a
percentage of total revenues during the current year quarter were impacted
by the significant growth in health plan premium revenues and the uninsured
discount and Medicaid pending policy changes. A table describing the impact
of adjustments to certain expenses and revenues and related ratios for our
acute care services segment and to certain statistical measures is included
in this release in the attached Supplemental Operating Measures Adjusted
for Comparative Analysis.

Adjusted EBITDA for the current year quarter was $82.9 million, an 11.3%
increase compared to the prior year quarter. A reconciliation of Adjusted
EBITDA to net income (loss) attributable to Vanguard Health Systems, Inc.
stockholders as determined in accordance with generally accepted accounting
principles for the quarters ended June 30, 2009 and 2010 is included in the
attached supplemental financial information.

The consolidated operating results for the current year quarter reflect a
1.8% increase in discharges and a 3.3% increase in adjusted discharges
compared to the prior year quarter. Emergency room visits increased 1.0%,
while inpatient surgeries and outpatient surgeries decreased 3.0% and 2.2%,
respectively, during the current year quarter compared to the prior year
quarter. General economic weakness in the United States economy continues
to impact demand for elective surgical procedures.

Total revenues for the year ended June 30, 2010 were $3,376.9 million, an
increase of $191.5 million or 6.0% from the prior year. Patient service
revenues and health plan premium revenues increased $29.8 million and
$161.7 million, respectively, from the prior year. Total revenues during
the current year were positively impacted by a 2.4% increase in adjusted
discharges but were negatively impacted by a 1.1% decrease in patient
revenue per adjusted discharge compared to the prior year. Absent the
previously discussed uninsured discount and Medicaid pending policy
changes, patient revenue per adjusted discharge would have increased 2.8%
during the current year compared to the prior year. Health plan premium
revenues increased 23.8% during the current year primarily due to the
significant enrollment increase associated with PHP’s new contract with
AHCCCS that went into effect on October 1, 2008.

Vanguard reported a loss from continuing operations of $44.6 million during
the current year compared to income from continuing operations of $32.1
million during the prior year. Net loss attributable to Vanguard Health
Systems, Inc. stockholders for the current year was $49.2 million compared
to net income attributable to Vanguard Health Systems, Inc. stockholders of
$28.6 million during the prior year. Each of these current year measures
was negatively impacted by the goodwill impairment loss related to our
Illinois hospitals recognized in December 2009 and by debt extinguishment
costs incurred to complete a refinancing of our indebtedness in January
2010. Many year over year comparisons of individual cost and expense items
as a percentage of total revenues, particularly for health plan claims
expense and the provision for doubtful accounts, were impacted by the
significant growth in health plan premium revenues and the uninsured
discount and Medicaid pending policy changes previously discussed. The
Supplemental Operating Measures Adjusted for Comparative Analysis table
included elsewhere in this release sets forth the impact of the uninsured
discount and Medicaid pending policy changes to certain expenses and
revenues and related ratios for our acute care services segment and to
certain statistical measures. Health plan claims expense as a percentage of
health plan premium revenues increased to 79.3% during the current year
compared to 77.5% during the prior year primarily as a result of changes to
capitation and supplemental payment rates, enrollee medical costs and
enrollee demographic mix under PHP’s new contract with AHCCCS that went
into effect on October 1, 2008.

Adjusted EBITDA was $326.6 million for the current year, an increase of
$23.9 million or 7.9% from the prior year. A reconciliation of Adjusted
EBITDA to net income (loss) attributable to Vanguard Health Systems, Inc.
stockholders as determined in accordance with generally accepted accounting
principles for the years ended June 30, 2009 and 2010 is included in the
attached supplemental financial information.

Cash flows from operating activities were $315.2 million for the current
year, an increase of $2.1 million from the prior year. Current year
operating cash flows were negatively impacted by AHCCCS’ deferral of the
June 2010 capitation and supplemental payments to PHP of approximately
$62.0 million until July 2010. Current year operating cash flows were
positively impacted by an improvement in net days revenue in accounts
receivable from 45 days at June 30, 2009 to 41 days at June 30, 2010. Cash
flows from operating activities were also positively impacted by the timing
of payments of accounts payable during the current year compared to the
prior year. Vanguard’s cash and cash equivalents balance was $257.6 million
at June 30, 2010 compared to $308.2 million at June 30, 2009.

On June 10, 2010, Vanguard entered into a definitive agreement to purchase
Detroit Medical Center (DMC), which owns and operates eight hospitals in
and around Detroit, Michigan with 1,734 licensed beds. Under the purchase
agreement, Vanguard will acquire all of DMC’s assets (other than donor
restricted and certain other assets) and assume all of its liabilities
(other than its outstanding bonds and other certain liabilities) for $417.0
million in cash, substantially all of which will be used to repay all such
non-assumed debt. The acquisition is pending review and approval by the
Michigan Attorney General. Detailed information regarding the purchase
price, assets acquired, liabilities assumed and future commitments related
to the DMC purchase are set forth in Vanguard’s Form 8-K filed with the
Securities and Exchange Commission on June 15, 2010. If approval is
obtained, Vanguard expects the DMC transaction to close during its second
quarter of fiscal 2011.

On July 14, 2010, certain of Vanguard’s subsidiaries issued $225.0 million
aggregate principal amount of 8% Senior Notes due 2018 (the Add-On Notes)
utilizing the same indenture governing the $950.0 million 8% Senior Notes
previously issued in January 2010. The Add-On Notes were issued at an
offering price of 96.250% plus accrued interest from January 29, 2010. The
proceeds from the issuance of the Add-On Notes will be used to fund a
portion of the DMC purchase price if such acquisition is approved by the
Michigan Attorney General or else used for general corporate purposes
including other potential acquisitions. Additional information regarding
the Add-On Notes is set forth in Vanguard’s Form 8-K filed with the
Securities and Exchange Commission on July 19, 2010.

On August 1, 2010, Vanguard completed the purchase of Westlake Hospital and
West Suburban Medical Center in the western suburbs of Chicago, Illinois
from Resurrection Health Care. As part of the purchase, Vanguard acquired
certain assets and assumed certain liabilities of these hospitals for a
total cash purchase price of approximately $45.0 million. These hospitals
have a combined 459 licensed beds and are each located within 10 miles of
Vanguard’s MacNeal Hospital. Additional information related to this
acquisition is set forth in Vanguard’s Form 8-K filed with the Securities
and Exchange Commission on August 4, 2010.

Vanguard will host a conference call for investors at 11:00 am EDT on
August 26, 2010. All interested investors are invited to access a live
audio broadcast of the call, via webcast. The live webcast can be accessed
on the home page of Vanguard’s Web site at www.vanguardhealth.com by
clicking on “Fourth Quarter Webcast” or at
http://visualwebcaster.com/event.asp?id=71303. If you are unable to
participate during the live webcast, the call will be available on a replay
basis on Vanguard’s Web site www.vanguardhealth.com. To access the replay,
click on the Investor Relations of www.vanguardhealth.com. The replay will
be available via this link for one year.

Vanguard owns and operates 17 acute care hospitals and complementary
facilities and services in Chicago, Illinois; Phoenix, Arizona; San
Antonio, Texas; and Massachusetts. Vanguard’s strategy is to develop
locally branded, comprehensive healthcare delivery networks in urban
markets. Vanguard will pursue acquisitions where there are opportunities to
partner with leading delivery systems in new urban markets or to increase
its presence in existing markets. Upon acquiring a facility or network of
facilities, Vanguard implements strategic and operational improvement
initiatives including expanding services, strengthening relationships with
physicians and managed care organizations, recruiting new physicians and
upgrading information systems and other capital equipment. These strategies
improve quality and network coverage in a cost effective and accessible
manner for the communities Vanguard serves.

This press release contains forward-looking statements within the meaning
of the federal securities laws, which are intended to be covered by the
safe harbors created thereby. These forward-looking statements include all
statements that are not historical statements of fact and those statements
regarding Vanguard’s intent, belief or expectations. Do not rely on any
forward-looking statements as such statements are subject to numerous
factors, risks and uncertainties that could cause Vanguard’s actual
outcomes, results, performance or achievements to be materially different
from those projected. These factors, risks and uncertainties include, among
others, Vanguard’s high degree of leverage and interest rate risk;
Vanguard’s ability to incur substantially more debt; operating and
financial restrictions in Vanguard’s debt agreements; Vanguard’s ability to
successfully implement its business strategies; Vanguard’s ability to
successfully integrate any future acquisitions; conflicts of interest that
may arise as a result of Vanguard’s control by a small number of
stockholders; the highly competitive nature of the healthcare business;
governmental regulation of the industry including Medicare and Medicaid
reimbursement levels; changes in Federal, state or local regulation
affecting the healthcare industry; the currently unknown effect on us of
the major federal healthcare reforms enacted by Congress in March 2010 or
other potential additional federal or state healthcare reforms; pressures
to contain costs by managed care organizations and other insurers and
Vanguard’s ability to negotiate acceptable terms with these third party
payers; the ability to attract and retain qualified management and
personnel, including physicians and nurses; claims and legal actions
relating to professional liabilities or other matters; the impacts of a
prolonged economic recession and tightened credit and capital markets on
Vanguard’s results of operations, financial position and cash flows
including its ability to successfully service its debt and remain in
compliance with debt covenants under its senior secured credit agreement;
Vanguard’s exposure to the increased amounts of and collection risks
associated with uninsured accounts and the co-pay and deductible portions
of insured accounts; Vanguard’s ability to maintain or increase patient
membership and control costs of its managed healthcare plans; the
availability and terms of capital to fund the expansion of Vanguard’s
business; the geographic concentration of Vanguard’s operations; the
technological and pharmaceutical improvements that increase the cost of
providing healthcare services or reduce the demand for such services; the
timeliness of reimbursement payments received under government programs;
the potential adverse impact of known and unknown government
investigations; and those factors, risks and uncertainties detailed in
Vanguard’s filings from time to time with the Securities and Exchange
Commission, including, among others, Vanguard’s Annual Reports on Form 10-K
and its Quarterly Reports on Form 10-Q.

Although Vanguard believes that the assumptions underlying the
forward-looking statements contained in this press release are reasonable,
any of these assumptions could prove to be inaccurate, and, therefore,
there can be no assurance that the forward-looking statements included in
this press release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein,
you should not regard the inclusion of such information as a representation
by Vanguard that its objectives and plans anticipated by the
forward-looking statements will occur or be achieved, or if any of them do,
what impact they will have on Vanguard’s results of operations and
financial condition. Vanguard undertakes no obligation to publicly release
any revisions to any forward-looking statements contained herein to reflect
events and circumstances occurring after the date hereof or to reflect the
occurrence of unanticipated events.

                          VANGUARD HEALTH SYSTEMS
        Condensed Consolidated Statements of Operations (Unaudited)
                              (In millions)


                                              Quarter ended June 30,
                                        ----------------------------------
                                              2009
                                          (as adjusted)         2010
                                        ----------------  ----------------
Patient service revenues                $ 629.3     76.1% $ 646.7     75.3%
Premium revenues                          197.2     23.9    211.7     24.7
                                        -------  -------  -------  -------
   Total revenues                         826.5    100.0    858.4    100.0
Costs and expenses:
   Salaries and benefits (includes
    stock compensation of $1.0 and $0.7,
    respectively)                         314.9     38.1    333.6     38.9
   Health plan claims expense             154.9     18.7    165.9     19.3
   Supplies                               116.1     14.0    116.7     13.6
   Provision for doubtful accounts         55.3      6.7     39.5      4.6
   Purchased services                      41.5      5.0     44.5      5.2
   Non-income taxes                        12.6      1.5     14.1      1.6
   Rents and leases                        10.8      1.3     11.0      1.3
   Other operating expenses                46.9      5.7     50.9      5.9
   Depreciation and amortization           34.2      4.1     37.7      4.4
   Interest, net                           27.0      3.3     30.8      3.6
   Debt extinguishment costs                  -        -      0.3        -
   Impairment loss                          6.2      0.8        -        -
   Other                                    0.7      0.1      5.6      0.7
                                        -------  -------  -------  -------
      Total costs and expenses            821.1     99.3    850.6     99.1
                                        -------  -------  -------  -------
Income from continuing operations
 before income taxes                        5.4      0.7      7.8      0.9
Income tax expense                         (3.3)    (0.4)    (4.4)    (0.5)
                                        -------  -------  -------  -------
Income from continuing operations           2.1      0.3      3.4      0.4
Income from discontinued operations,
 net of taxes                               0.6      0.1      0.2        -
                                        -------  -------  -------  -------
Net income                                  2.7      0.3      3.6      0.4
Less: Net income attributable to
 non-controlling interests                 (0.9)    (0.1)    (0.8)    (0.1)
                                        -------  -------  -------  -------
Net income attributable to Vanguard
 Health Systems, Inc. stockholders      $   1.8      0.2% $   2.8      0.3%
                                        =======  =======  =======  =======




                      VANGUARD HEALTH SYSTEMS, INC.
        Condensed Consolidated Statements of Operations (Unaudited)
                              (In millions)


                                            Year ended June 30,
                                ------------------------------------------
                                        2009                  2010
                                --------------------  --------------------
Patient service revenues        $ 2,507.4       78.7% $ 2,537.2      75.1%
Premium revenues                    678.0       21.3      839.7      24.9
                                ---------  ---------  ---------  --------
   Total revenues                 3,185.4      100.0    3,376.9     100.0
Costs and expenses:
   Salaries and benefits
    (includes stock
    compensation
    of $4.4 and $4.2,
    respectively)                 1,233.8       38.7    1,296.2      38.4
   Health plan claims expense       525.6       16.5      665.8      19.7
   Supplies                         455.5       14.3      456.1      13.5
   Provision for doubtful
    accounts                        210.3        6.6      152.5       4.5
   Purchased services               163.8        5.1      179.5       5.3
   Non-income taxes                  52.2        1.6       52.9       1.6
   Rents and leases                  42.6        1.3       43.8       1.3
   Other operating expenses         203.3        6.4      207.7       6.2
   Depreciation and
    amortization                    128.9        4.0      139.6       4.1
   Interest, net                    111.6        3.5      115.5       3.4
   Debt extinguishment costs            -          -       73.5       2.2
   Impairment loss                    6.2        0.2       43.1       1.3
   Other                              2.7        0.1        9.1       0.3
                                ---------  ---------  ---------  --------
      Total costs and expenses    3,136.5       98.5    3,435.3     101.7
                                ---------  ---------  ---------  --------
Income (loss) from continuing
 operations before income taxes      48.9        1.5      (58.4)     (1.7)
Income tax benefit (expense)        (16.8)      (0.5)      13.8       0.4
                                ---------  ---------  ---------  --------
Income (loss) from continuing
 operations                          32.1        1.0      (44.6)     (1.3)
Loss from discontinued
 operations, net of taxes            (0.3)      (0.0)      (1.7)     (0.1)
                                ---------  ---------  ---------  --------
Net income (loss)                    31.8        1.0      (46.3)     (1.4)
Less: Net income attributable
 to non-controlling interests        (3.2)      (0.1)      (2.9)     (0.1)
                                ---------  ---------  ---------  --------
Net income (loss) attributable
 to Vanguard Health Systems, Inc.
 stockholders                   $    28.6        0.9% $   (49.2)     (1.5)%
                                =========  =========  =========  ========




                      VANGUARD HEALTH SYSTEMS, INC.
              Supplemental Financial Information (Unaudited)
  Reconciliation of Adjusted EBITDA to Net Income (Loss) Attributable to
                Vanguard Health Systems, Inc. Stockholders
                              (In millions)


                                          Quarter Ended      Year Ended
                                             June 30,          June 30,
                                        ----------------  ----------------
                                          2009     2010     2009     2010
                                        -------  -------  -------  -------
Net income (loss) attributable to
 Vanguard Health Systems, Inc.
 stockholders                           $   1.8  $   2.8  $  28.6  $ (49.2)
Interest, net                              27.0     30.8    111.6    115.5
Income tax expense (benefit)                3.3      4.4     16.8    (13.8)
Depreciation and amortization              34.2     37.7    128.9    139.6
Non-controlling interests                   0.9      0.8      3.2      2.9
Loss (gain) on disposal of assets          (0.2)     1.4     (2.3)     1.8
Equity method income                       (0.4)    (0.1)    (0.8)    (0.9)
Stock compensation                          1.0      0.7      4.4      4.2
Monitoring fees and expenses                1.3      1.2      5.2      5.1
Realized loss on investments                  -        -      0.6        -
Impairment loss                             6.2        -      6.2     43.1
Acquisition related expenses                  -      3.1        -      3.1
Debt extinguishment costs                     -      0.3        -     73.5
Discontinued operations, net of taxes      (0.6)    (0.2)     0.3      1.7
                                        -------  -------  -------  -------
    Adjusted EBITDA (1)                 $  74.5  $  82.9  $ 302.7  $ 326.6
                                        =======  =======  =======  =======


(1) Adjusted EBITDA is defined as income before interest expense (net of
    interest income), income taxes, depreciation and amortization,
    non-controlling interests, gain or loss on disposal of assets, equity
    method income, stock compensation, monitoring fees and expenses,
    realized holding loss on investments, acquisition related expenses,
    debt extinguishment costs, impairment loss and discontinued operations,
    net of taxes. Adjusted EBITDA is not intended as a substitute for net
    income (loss) attributable to Vanguard Health Systems, Inc.
    stockholders, operating cash flows or other cash flow data determined
    in accordance with accounting principles generally accepted in the
    United States. Due to varying methods of calculation, Adjusted EBITDA
    as presented may not be comparable to similarly titled measures of
    other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                        Consolidated Balance Sheets
                              (In millions)


                                                      June 30,   June 30,
ASSETS                                                  2009       2010
                                                      ---------  ---------
Current assets:
  Cash and cash equivalents                           $   308.2  $   257.6
  Restricted cash                                           1.9        2.3
  Accounts receivable, net of allowance for doubtful
   accounts of approximately $121.5 and $75.6 at
   June 30, 2009 and June 30, 2010, respectively          275.3      270.4
  Inventories                                              48.3       49.6
  Deferred tax assets                                      29.6       21.9
  Prepaid expenses and other current assets                68.4      119.2
                                                      ---------  ---------
    Total current assets                                  731.7      721.0
Property, plant and equipment, net of accumulated
 depreciation                                           1,174.1    1,203.8
Goodwill                                                  692.1      649.1
Intangible assets, net of accumulated amortization         54.6       66.0
Deferred tax assets, noncurrent                            38.0       50.0
Investments in auction rate securities                     21.6       19.8
Other assets                                               19.0       19.9
                                                      ---------  ---------
    Total assets                                      $ 2,731.1  $ 2,729.6
                                                      =========  =========

LIABILITIES AND  EQUITY
Current liabilities:
  Accounts payable                                    $   127.9  $   194.8
  Accrued salaries and benefits                           133.9      144.9
  Accrued health plan claims and settlements              117.6      149.8
  Accrued interest                                         13.2       41.4
  Other accrued expenses and current liabilities           79.5       76.9
  Current maturities of long-term debt                      8.0        8.2
                                                      ---------  ---------
    Total current liabilities                             480.1      616.0
Professional and general liability and workers
 compensation reserves                                     76.7       83.6
Other liabilities                                          34.9       31.6
Long-term debt, less current maturities                 1,543.6    1,743.8
Commitments and contingencies
Equity:
  Vanguard Health Systems, Inc. stockholders' equity:
   Common stock                                               -          -
   Additional paid-in capital                             651.3      354.9
   Accumulated other comprehensive loss                    (6.8)      (2.5)
   Retained deficit                                       (56.7)    (105.9)
                                                      ---------  ---------
    Total Vanguard Health Systems, Inc. stockholders'
     equity                                               587.8      246.5
  Non-controlling interests                                 8.0        8.1
                                                      ---------  ---------
    Total equity                                          595.8      254.6
                                                      ---------  ---------
    Total liabilities and equity                      $ 2,731.1  $ 2,729.6
                                                      =========  =========




                         VANGUARD HEALTH SYSTEMS, INC.
                     Consolidated Statements of Cash Flows
                                 (In millions)


                                                            Year Ended
                                                             June 30,
                                                        ------------------
                                                          2009      2010
                                                        --------  --------
Operating activities:

Net income (loss)                                       $   31.8  $  (46.3)
Adjustments to reconcile net income (loss) to net cash
 provided by operating activities:
  Loss from discontinued operations                          0.3       1.7
  Depreciation and amortization                            128.9     139.6
  Provision for doubtful accounts                          210.3     152.5
  Amortization of loan costs and accretion of principal
   on notes                                                 27.2      11.7
  Loss (gain) on disposal of assets                         (2.3)      1.8
  Stock compensation                                         4.4       4.2
  Deferred income taxes                                      6.4      (8.5)
  Impairment loss                                            6.2      43.1
  Realized holding loss on investments                       0.6         -
  Acquisition related expenses                                 -       3.1
  Debt extinguishment costs                                    -      73.5
  Changes in operating assets and liabilities:
   Accounts receivable                                    (185.6)   (148.3)
   Inventories                                               1.0      (1.3)
   Prepaid expenses and other current assets               (12.7)    (80.5)
   Accounts payable                                        (27.5)     67.1
   Accrued expenses and other liabilities                  122.7     102.8
                                                        --------  --------
Net cash provided by operating activities - continuing
 operations                                                311.7     316.2
Net cash provided by (used in) operating activities -
 discontinued operations                                     1.4      (1.0)
                                                        --------  --------
Net cash provided by operating activities                  313.1     315.2

Investing activities:
Acquisitions and related expenses                           (4.4)     (4.6)
Capital expenditures                                      (132.0)   (155.9)
Proceeds from asset dispositions                             4.9       2.0
Sales of auction rate securities                               -       1.8
Other                                                       (2.0)      0.3
                                                        --------  --------
Net cash used in investing activities - continuing
 operations                                               (133.5)   (156.4)
Net cash used in investing activities - discontinued
 operations                                                 (0.1)     (0.1)
                                                        --------  --------
Net cash used in investing activities                     (133.6)   (156.5)

Financing activities:
Payments of long-term debt                                  (7.8) (1,557.4)
Proceeds from debt borrowings                                  -   1,751.3
Payments of refinancing costs and fees                         -     (93.6)
Repurchases of stock and stock options                      (0.2)   (300.6)
Payments related to derivative instrument with
 financing element                                             -      (6.2)
Distributions paid to non-controlling interests and
 other                                                      (4.9)     (2.8)
                                                        --------  --------
Net cash used in financing activities                      (12.9)   (209.3)
                                                        --------  --------
Net increase (decrease) in cash and cash equivalents       166.6     (50.6)
Cash and cash equivalents, beginning of year               141.6     308.2
                                                        --------  --------
Cash and cash equivalents, end of year                  $  308.2  $  257.6
                                                        ========  ========




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                Three months ended June 30, 2009
                      ----------------------------------------------------
                       Acute
                       Care     % of     Health   % of    Elimin-  Consol-
                     Services Revenues   Plans  Revenues  ations   idated
                      -------  ------   -------- -------  -------  -------
Patient service
 revenues(1)          $ 638.3   100.0%  $      -       -% $  (9.0) $ 629.3
Premium revenues            -       -      197.2   100.0        -    197.2
                      -------  ------   -------- -------  -------  -------
   Total revenues       638.3   100.0      197.2   100.0     (9.0)   826.5

Salaries and benefits
 (excludes stock
 compensation)          306.0    47.9        7.9     4.0        -    313.9
Health plan claims
 expense                    -       -      163.9    83.1     (9.0)   154.9
Supplies                116.0    18.2        0.1     0.1        -    116.1
Provision for
 doubtful
 accounts                55.3     8.7          -       -        -     55.3
Other operating
 expenses               102.2    16.0        9.6     4.9        -    111.8
                      -------  ------   -------- -------  -------  -------
   Total operating
    expenses            579.5    90.8      181.5    92.0     (9.0)   752.0
                      -------  ------   -------- -------  -------  -------
   Segment EBITDA(2)     58.8     9.2       15.7     8.0        -     74.5
Less:
 Interest, net           26.8     4.2        0.2     0.1        -     27.0
 Depreciation and
  amortization           33.1     5.2        1.1     0.6        -     34.2
 Equity method income    (0.4)   (0.1)         -       -        -     (0.4)
 Stock compensation       1.0     0.2          -       -        -      1.0
 Gain on disposal of
  assets                 (0.2)   (0.0)         -       -        -     (0.2)
 Monitoring fees and
  expenses                1.3     0.2          -       -        -      1.3
Impairment loss           6.2     1.0          -       -        -      6.2
                      -------  ------   -------- -------  -------  -------
 Income (loss) from
  continuing operations
  before income taxes $  (9.0)   (1.4)% $   14.4     7.3% $     -  $   5.4
                      =======  ======   ======== =======  =======  =======


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the corresponding
    medical claims expenses incurred by the health plans for those
    services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of non-cash
    depreciation of tangible assets and amortization of intangible assets,
    much of which results from acquisitions accounted for under the
    purchase method of accounting. Segment EBITDA also eliminates the
    effects of changes in interest rates which management believes relate
    to general trends in global capital markets, but are not necessarily
    indicative of the operating performance of Vanguard's segments.
    Management believes that Segment EBITDA provides useful information
    about the financial performance of Vanguard's segments to investors,
    lenders, financial analysts and rating agencies. Additionally,
    management believes that investors and lenders view Segment EBITDA as
    an important factor in making investment decisions and assessing the
    value of Vanguard. Segment EBITDA is not a substitute for net income
    (loss), operating cash flows or other cash flow statement data
    determined in accordance with accounting principles generally accepted
    in the United States. Segment EBITDA, as presented, may not be
    comparable to similar  measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                               Three months ended June 30, 2010
                  --------------------------------------------------------
                   Acute
                    Care      % of    Health     % of   Elimina-  Consoli-
                  Services  Revenues   Plans   Revenues  tions     dated
                  --------  -------   -------  -------  --------  --------
Patient service
 revenues(1)      $  657.8    100.0%  $     -        -% $  (11.1) $  646.7
Premium revenues         -        -     211.7    100.0         -     211.7
                  --------  -------   -------  -------  --------  --------
 Total revenues      657.8    100.0     211.7    100.0     (11.1)    858.4

Salaries and
 benefits
 (excludes stock
 compensation)       324.0     49.3       8.9      4.2         -     332.9
Health plan
 claims expense          -        -     177.0     83.6     (11.1)    165.9
Supplies             116.7     17.7         -        -         -     116.7
Provision for
 doubtful
 accounts             39.5      6.0         -        -         -      39.5
Other operating
 expenses            110.8     16.8       9.7      4.6         -     120.5
                  --------  -------   -------  -------  --------  --------
  Total operating
   expenses          591.0     89.8     195.6     92.4     (11.1)    775.5
                  --------  -------   -------  -------  --------  --------
  Segment EBITDA(2)   66.8     10.2      16.1      7.6         -      82.9
Less:
 Interest, net        31.2      4.7      (0.4)    (0.2)        -      30.8
 Depreciation and
  amortization        36.6      5.6       1.1      0.5         -      37.7
 Equity method
  income              (0.1)    (0.0)        -        -         -      (0.1)
 Stock compensation    0.7      0.1         -        -         -       0.7
 Loss on disposal
  of assets            1.4      0.2         -        -         -       1.4
 Monitoring fees
  and expenses         1.2      0.2         -        -         -       1.2
 Acquisition
  related expenses     3.1      0.5         -        -         -       3.1
 Debt
  extinguishment
  costs                0.3        -         -        -         -       0.3
                  --------  -------   -------  -------  --------  --------
  Income (loss)
   from continuing
   operations
   before income
   taxes          $   (7.6)    (1.2)% $  15.4      7.3% $      -  $    7.8
                  ========  =======   =======  =======  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the
    corresponding medical claims expenses incurred by the health plans for
    those services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of
    non-cash depreciation of tangible assets and amortization of
    intangible assets, much of which results from acquisitions accounted
    for under the purchase method of accounting. Segment EBITDA also
    eliminates the effects of changes in interest rates which management
    believes relate to general trends in global capital markets, but are
    not necessarily indicative of the operating performance of Vanguard's
    segments. Management believes that Segment EBITDA provides useful
    information about the financial performance of Vanguard's segments to
    investors, lenders, financial analysts and rating agencies.
    Additionally, management believes that investors and lenders view
    Segment EBITDA as an important factor in making investment decisions
    and assessing the value of Vanguard. Segment EBITDA is not a
    substitute for net income (loss), operating cash flows or other cash
    flow statement data determined in accordance with accounting
    principles generally accepted in the United States. Segment EBITDA,
    as presented, may not be comparable to similar
    measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                  Year ended June 30, 2009
                  --------------------------------------------------------
                    Acute
                    Care      % of    Health    % of    Elimina-  Consoli-
                  Services  Revenues  Plans   Revenues    tions     dated
                  --------  --------  ------  --------  --------  --------
Patient service
 revenues(1)      $2,541.4     100.0% $    -         -% $  (34.0) $2,507.4
Premium revenues         -         -   678.0     100.0         -     678.0
                  --------  --------  ------  --------  --------  --------
  Total revenues   2,541.4     100.0   678.0     100.0     (34.0)  3,185.4

Salaries and
 benefits
 (excludes stock
 compensation)     1,198.8      47.2    30.6       4.5         -   1,229.4
Health plan
 claims expense          -         -   559.6      82.5     (34.0)    525.6
Supplies             455.2      17.9     0.3         -         -     455.5
Provision for
 doubtful
 accounts            210.3       8.3       -         -         -     210.3
Other operating
 expenses            425.5      16.7    36.4       5.4         -     461.9
                  --------  --------  ------  --------  --------  --------
  Total operating
   expenses        2,289.8      90.1   626.9      92.5     (34.0)  2,882.7
                  --------  --------  ------  --------  --------  --------
  Segment EBITDA(2)  251.6       9.9    51.1       7.5         -     302.7
Less:
 Interest, net       112.2       4.4    (0.6)     (0.1)        -     111.6
 Depreciation and
  amortization       124.8       4.9     4.1       0.6         -     128.9
 Equity method
  income              (0.8)     (0.0)      -         -         -      (0.8)
 Stock
  compensation         4.4       0.2       -         -         -       4.4
 Gain on disposal
  of assets           (2.3)     (0.1)      -         -         -      (2.3)
 Monitoring fees
  and expenses         5.2       0.2       -         -         -       5.2
 Realized holding
  loss on
  investments          0.6         -       -         -         -       0.6
 Impairment loss       6.2       0.2       -         -         -       6.2
                  --------  --------  ------  --------  --------  --------
  Income from
   continuing
   operations
   before income
   taxes          $    1.3       0.1% $ 47.6       7.0% $      -  $   48.9
                  ========  ========  ======  ========  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the
    corresponding medical claims expenses incurred by the health plans for
    those services

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of
    non-cash depreciation of tangible assets and amortization of
    intangible assets, much of which results from acquisitions accounted
    for under the purchase method of accounting. Segment EBITDA also
    eliminates the effects of changes in interest rates which management
    believes relate to general trends in global capital markets, but are
    not necessarily indicative of the operating performance of Vanguard's
    segments. Management believes that Segment EBITDA provides useful
    information about the financial performance of Vanguard's segments to
    investors, lenders, financial analysts and rating agencies.
    Additionally, management believes that investors and lenders view
    Segment EBITDA as an important factor in making investment decisions
    and assessing the value of Vanguard. Segment EBITDA is not a
    substitute for net income (loss), operating cash flows or other cash
    flow statement data determined in accordance with accounting
    principles generally accepted in the United States. Segment EBITDA,
    as presented, may not be comparable to similar measures of other
    companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                  Year ended June 30, 2010
                  --------------------------------------------------------
                    Acute
                    Care      % of    Health     % of   Elimina-  Consoli-
                  Services  Revenues   Plans   Revenues  tions     dated
                  --------  -------   -------  -------  --------  --------
Patient service
 revenues(1)      $2,580.0    100.0 % $     -        -% $  (42.8) $2,537.2
Premium revenues         -        -     839.7    100.0         -     839.7
                  --------  -------   -------  -------  --------  --------
  Total revenues   2,580.0    100.0     839.7    100.0     (42.8)  3,376.9

Salaries and
 benefits
 (excludes stock
 compensation)     1,257.9     48.8      34.1      4.1         -   1,292.0
Health plan
 claims expense          -        -     708.6     84.4     (42.8)    665.8
Supplies             456.0     17.7       0.1        -         -     456.1
Provision for
 doubtful
 accounts            152.5      5.9         -        -         -     152.5
Other operating
 expenses            447.0     17.3      36.9      4.4         -     483.9
                  --------  -------   -------  -------  --------  --------
  Total operating
   expenses        2,313.4     89.7     779.7     92.9     (42.8)  3,050.3
                  --------  -------   -------  -------  --------  --------
  Segment EBITDA(2)  266.6     10.3      60.0      7.1         -     326.6
Less:
 Interest, net       116.5      4.5      (1.0)    (0.1)        -     115.5
 Depreciation and
  amortization       135.2      5.2       4.4      0.5         -     139.6
 Equity method
  income              (0.9)    (0.0)        -        -         -      (0.9)
 Stock
  compensation         4.2      0.2         -        -         -       4.2
 Loss on disposal
  of assets            1.8      0.1         -        -         -       1.8
 Monitoring fees
  and expenses         5.1      0.2         -        -         -       5.1
 Acquisition
  related expenses     3.1      0.1         -        -         -       3.1
 Debt
  extinguishment
  costs               73.5      2.8         -        -         -      73.5
 Impairment loss      43.1      1.7         -        -         -      43.1
                  --------  -------   -------  -------  --------  --------
  Income (loss)
   from
   continuing
   operations
   before income
   taxes          $ (115.0)    (4.5)% $  56.6      6.7% $      -  $  (58.4)
                  ========  =======   =======  =======  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the corresponding
    medical claims expenses incurred by the health plans for  those
services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of non-cash
    depreciation of tangible assets and amortization of intangible assets,
    much of which results from acquisitions accounted for under the
    purchase method of accounting. Segment EBITDA also eliminates the
    effects of changes in interest rates which management believes relate
    to general trends in global capital markets, but are not necessarily
    indicative of the operating performance of Vanguard's segments.
    Management believes that Segment EBITDA provides useful information
    about the financial performance of Vanguard's segments to investors,
    lenders, financial analysts and rating agencies. Additionally,
    management believes that investors and lenders view Segment EBITDA as
    an important factor in making investment decisions and assessing the
    value of Vanguard. Segment EBITDA is not a substitute for net income
    (loss), operating cash flows or other cash flow statement data
    determined in accordance with accounting principles generally accepted
    in the United States. Segment EBITDA, as presented, may not be
    comparable to similar measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Selected Operating Statistics
                                (Unaudited)

                                                Three months ended
                                                     June 30,
                                                 ----------------
                                                   2009     2010   % Change
                                                 -------  -------  -------
Number of hospitals at end of period                  15       15
Licensed beds at end of period                     4,135    4,135
Discharges                                        41,400   42,159      1.8%
Adjusted discharges                               73,210   75,620      3.3
Adjusted discharges - hospitals                   69,258   71,657      3.5
Average length of stay                              4.18     4.09     (2.2)
Patient days                                     173,022  172,388     (0.4)
Adjusted patient days                            305,966  309,209      1.1
Adjusted patient days - hospitals                289,447  293,003      1.2
Patient revenue per adjusted discharge           $ 8,422  $ 8,407     (0.2)
Patient revenue per adjusted discharge -
 hospitals                                       $ 8,850  $ 8,560     (3.3)
Inpatient surgeries                                9,530    9,244     (3.0)
Outpatient surgeries                              19,521   19,084     (2.2)
Emergency room visits                            158,936  160,523      1.0%

Charity care and uninsured discounts as a
 percent of acute care segment revenues
 (prior to these discounts)(1)                       4.9%    10.8%

Provision for doubtful accounts as a percent of
 acute care services segment revenues (prior to
 charity and uninsured discounts)(1)                 8.2%     5.4%

Net patient revenue payer mix:
   Medicare                                         24.8%    25.0%
   Medicaid                                          7.7      7.6
   Managed Medicare                                 14.7     14.7
   Managed Medicaid                                  9.1      9.3
   Managed care                                     34.0     35.2
   Commercial                                        0.9      1.0
   Self pay                                          8.8      7.2
                                                 -------  -------
      Total                                        100.0%   100.0%
                                                 =======  =======

Discharges by payer:
   Medicare                                         26.7%    27.8%
   Medicaid(1)                                       9.7      9.3
   Managed Medicare                                 16.5     16.3
   Managed Medicaid                                 14.3     15.2
   Managed care                                     28.3     26.4
   Commercial                                        0.4      0.4
   Self pay(1)                                       4.1      4.6
                                                 -------  -------
      Total                                        100.0%   100.0%
                                                 =======  =======


(1) See Supplemental Operating Measures Adjusted For Comparative Analysis
    for the impact to the ratio of charity and uninsured discounts as a
    percent of acute care services segment revenues, the ratio of
    provision for doubtful accounts as a percent of acute care services
    segment revenues and Medicaid and self pay discharges of the change
    in our Medicaid pending policy during the three months ended June
    30, 2010.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Selected Operating Statistics
                          (Unaudited) (continued)


                                            Year ended June 30,
                                           --------------------
                                             2009       2010     % Change
                                           ---------  ---------  ---------
Number of hospitals at end of period              15         15
Licensed beds at end of period                 4,135      4,135
Discharges                                   167,880    168,370        0.3%
Adjusted discharges                          288,807    295,702        2.4
Adjusted discharges - hospitals              274,767    280,437        2.1
Average length of stay                          4.23       4.17       (1.4)
Patient days                                 709,952    701,265       (1.2)
Adjusted patient days                      1,221,345  1,231,604        0.8
Adjusted patient days - hospitals          1,161,967  1,168,027        0.5
Patient revenue per adjusted discharge     $   8,503  $   8,408       (1.1)
Patient revenue per adjusted discharge -
 hospitals                                 $   8,623  $   8,516       (1.2)
Inpatient surgeries                           37,970     37,320       (1.7)
Outpatient surgeries                          76,378     75,969       (0.5)
Emergency room visits                        605,729    626,237        3.4%

Charity care and uninsured discounts as a
 percent of acute care services segment
 revenues (prior to these discounts)             3.9%      10.5%

Provision for doubtful accounts as a
 percent of acute care services segment
 revenues (prior to charity and uninsured
 discounts)(1)                                   8.0%       5.3%

Net patient revenue payer mix:
   Medicare                                     25.3%      25.5%
   Medicaid                                      7.9        7.4
   Managed Medicare                             14.1       14.8
   Managed Medicaid                              8.8        9.5
   Managed care                                 34.7       34.9
   Commercial                                    0.9        1.1
   Self pay                                      8.3        6.8
                                           ---------  ---------
      Total                                    100.0%     100.0%
                                           =========  =========

Discharges by payer:
   Medicare                                     27.1%      27.5%
   Medicaid (1)                                 10.2        8.8
   Managed Medicare                             16.0       16.3
   Managed Medicaid                             13.8       15.3
   Managed care                                 29.2       26.8
   Commercial                                    0.3        0.4
   Self pay (1)                                  3.4        4.9
                                           ---------  ---------
      Total                                    100.0%     100.0%
                                           =========  =========

(1) See Supplemental Operating Measures Adjusted For Comparative Analysis
    for the impact to the ratio of charity and uninsured discounts as a
    percent of acute care services segment revenues, the ratio of provision
    for doubtful accounts as a percent of acute care services segment
    revenues and Medicaid and self pay discharges of the change in our
    Medicaid pending policy during the year ended June 30, 2010.




                      VANGUARD HEALTH SYSTEMS, INC.
    Supplemental Operating Measures Adjusted for Comparative Analysis
                 For the three months ended June 30, 2010
          (dollars in millions, except for statistical measures)
                                (Unaudited)


                         Impact of Policy           % of Segment Revenues
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts discounts pending amounts   basis  --------------
                   (1)      (2)      (3)     (4)     2010    2009    2010
                 ------- --------  ------  -------  ------  ------  ------
Acute care
 services
 segment:
 Total
  revenues(5)    $ 657.8 $   33.5  $ (4.7) $ 686.6   100.0%  100.0%  100.0%
 Salaries and
  benefits(8)    $ 324.7 $      -  $    -  $ 324.7    49.4    47.6    47.3
 Supplies        $ 116.7 $      -  $    -  $ 116.7    17.7    18.0    17.0
 Provision for
  doubtful
  accounts       $  39.5 $   33.5  $ (3.6) $  69.4     6.0     9.6    10.1
 Other operating
  expenses       $ 110.8 $      -  $    -  $ 110.8    16.8    15.8    16.1
 Total operating
  expenses       $ 591.7 $   33.5  $ (3.6) $ 621.6    90.0%   91.0 %  90.5%


                                                    % of Segment Revenues
                                                     Prior to Charity and
                         Impact of Policy            Uninsured Discounts
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts discounts pending amounts   basis  --------------
                   (1)      (2)      (3)     (4)     2010     2009   2010
                 ------- --------  ------  -------  ------  ------  ------
Uncompensated
 care(6)         $ 117.8 $  (21.2) $ (3.6) $  93.0    16.0%   12.4%   13.1%
Total revenues,
 prior
 to charity(7)   $ 681.3 $   33.5  $ (4.7) $ 710.1


                  2010                           2010
              Statistical   2010      2010   Statistical   2009    Current
Vanguard        Measure   Uninsured Medicaid   Measure   Measure    year
consolidated:      as     discounts  pending      as        as    change as
               reported      (2)       (3)    adjusted  adjusted  adjusted
                -------   --------   ------    -------   -------   ------
Patient revenue
 per total
 adjusted
 discharge      $ 8,407   $    443   $  (62)   $ 8,788   $ 8,516      3.2%
Self-pay
 discharges       1,942          -     (600)     1,342     1,526    (12.1)%
Medicaid
 discharges       3,910          -      600      4,510     4,197      7.5%




                      VANGUARD HEALTH SYSTEMS, INC.
    Supplemental Operating Measures Adjusted for Comparative Analysis
                     For the year ended June 30, 2010
          (dollars in millions, except for statistical measures)
                                (Unaudited)


                         Impact of Policy           % of Segment Revenues
                             Changes               -----------------------
                 GAAP-   ---------------   Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted GAAP    adjusted(4)
                 amounts discounts pending amounts  basis  ---------------
                   (1)      (2)      (3)     (4)    2010    2009     2010
                 -------- ------  ------  -------- ------  -----   -------
Acute care
 services
 segment:
 Total
  revenues(5)    $2,580.0 $128.7  $(22.9) $2,685.8  100.0% 100.0%    100.0%
 Salaries and
  benefits(8)    $1,262.1 $    -  $    -  $1,262.1   48.9   47.2      47.0
 Supplies        $  456.0 $    -  $    -  $  456.0   17.7   17.9      17.0
 Provision for
  doubtful
  accounts       $  152.5 $128.7  $(22.3) $  258.9    5.9    8.5       9.6
 Other operating
  expenses       $  447.0 $    -  $    -  $  447.0   17.3   16.7      16.6
 Total operating
  expenses       $2,317.6 $128.7  $(22.3) $2,424.0   89.8%  90.3%     90.3%


                                                    % of Segment Revenues
                                                     Prior to Charity and
                         Impact of Policy            Uninsured Discounts
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts   dis-   pending  amounts  basis  ---------------
                   (1)   counts(2)  (3)     (4)      2010   2009     2010
                 -------- ------  ------  --------  -----  -----    ------
Uncompensated
 care(6)         $  455.9 $(87.0) $(22.3) $  346.6   15.8%  11.6%     12.5%

Total revenues,
 prior to
 charity(7)      $2,667.7 $128.7  $(22.9) $2,773.5


                  2010                           2010
              Statistical   2010      2010   Statistical   2009    Current
Vanguard        Measure   Uninsured Medicaid   Measure   Measure    year
consolidated:      as     discounts  pending      as        as    change as
               reported      (2)       (3)    adjusted  adjusted  adjusted
                -------   --------   ------    -------   -------   ------
Patient revenue
 per total
 adjusted
 discharge      $ 8,408   $    435   $  (79)   $ 8,764   $ 8,527      2.8%
Self-pay
 discharges       8,168          -   (2,717)     5,451     5,483     (0.6)%
Medicaid
 discharges      14,867          -    2,717     17,584    17,235      2.0%


(1) Amounts reflected in or components of amounts reflected in the
    segment information tables included in this release. These amounts
    are based upon revenues or expenses determined in accordance with
    accounting principles generally accepted in the United States.

(2) Includes the impact of the uninsured discount policy implemented
    for Vanguard's Illinois hospitals effective April 1, 2009 and for
    it Phoenix and San Antonio hospitals effective July 1, 2009. Under
    this policy, Vanguard applies an uninsured discount (calculated as
    a standard percentage of gross revenues) at the time of patient
    billing and includes the discount as a reduction of revenues. This
    uninsured discount program applies to patients receiving hospital
    services who have no insurance coverage and do not otherwise meet
    Vanguard's charity care guidelines. Vanguard recorded a total of
    $11.7 million and $54.7 million of uninsured discounts relates to
    its acute care services segment during the three months ended June
    30, 2009 and 2010, respectively. Of these amounts $7.6 million and
    $33.5 million for the three months ended June 30, 2009 and 2010,
    respectively, related to non-Medicaid pending accounts that reduced
    revenues as a result of implementing this policy. Vanguard recorded
    a total of $11.7 million and $215.7 million of uninsured discounts
    related to its acute care services segment during the years ended
    June 30, 2009 and 2010, respectively. Of these amounts, $7.6 million
    and $128.7 million for the years ended June 30, 2009 and 2010,
    respectively, related to non-Medicaid pending accounts that reduced
    revenues as a result of implementing this policy.

(3) Includes the impact of Vanguard's policy change for accounts pending
    Medicaid qualification. Prior to the implementation of its new
    uninsured discount policy, Vanguard classified accounts pending
    Medicaid qualification as Medicaid revenues (and Medicaid discharges)
    and recorded a contractual discount for these accounts based upon
    the average Medicaid reimbursement rate for each specific state until
    qualification was confirmed. Vanguard implemented a new Medicaid
    pending policy for all of its hospitals whereby Medicaid pending
    accounts are classified as self-pay revenues (and self-pay discharges)
    with an uninsured discount applied. The balance of these accounts is
    subject to Vanguard's allowance for doubtful accounts policy. For
    those accounts that subsequently qualify for Medicaid coverage, the
    uninsured discount is reversed and the account is reclassified to
    Medicaid revenues (and Medicaid discharges) with the appropriate
    contractual discount applied. The difference between the
    state-specific Medicaid contractual discounts under the previous
    policy and the uninsured discount percentage applied to Medicaid
    pending accounts under the new policy increased total revenues by
    $0.7 million, $4.7 million, $0.7 million and $22.9 million for the
    three months ended June 30, 2009 and 2010 and the years ended June
    30, 2009 and 2010, respectively. The provision for doubtful accounts
    recorded for Medicaid pending accounts, after the uninsured discounts
    were applied, were $1.0 million, $3.6 million, $1.0 million and $22.3
    million for the three months ended June 30, 2009 and 2010 and the
    years ended June 30, 2009 and 2010, respectively.

(4) Revenues, certain expenses and those expenses as a percentage of
    revenues for the acute care services segment for the three months and
    year ended June 30, 2010 have been adjusted to allow for comparative
    measurement on a basis consistent with the three months and year ended
    June 30, 2009 (before implementation of the majority of the uninsured
    discount policy or the change to the Medicaid pending policy).
    Management believes these non-GAAP measures will provide investors,
    analysts and general users of this financial information an effective
    means to compare the operating results of Vanguard's acute care
    services segment for the current year periods to those of the prior
    year periods. However, these non-GAAP operating measures are not
    meant to replace GAAP-basis revenues, expenses or expenses as a
    percentage of revenues as operating performance indicators for the
    acute care services segment.

(5) Total revenues for the acute care services segment represent revenues
    prior to the elimination in consolidation of revenues earned by
    Vanguard's hospitals for services provided to enrollees in Vanguard's
    owned health plans.

(6) Uncompensated care is defined as the sum of uninsured discounts,
    charity deductions and the provision for doubtful accounts.

(7) Represents total revenues for the acute care services segment plus
    charity deductions.

(8) Includes stock compensation.

MOUNTAINSIDE, NJ–(Marketwire – August 25, 2010) –  PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors. 

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (“XGen”), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. More specifically, the investment may never occur negating the agreement, product performance and/or side effects may necessitate termination of the joint venture, the implementation of the agreement may not succeed and inadequate or no business may develop causing the failure of the joint venture and there are inherent risks in foreign operations, particularly those in the Mideast. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Click here to see all recent news from this company

PHOENIX, AZ–(Marketwire – August 25, 2010) –  Remuda Ranch Programs for Eating and Anxiety Disorders reports in the past five years, self-injury, particularly cutting oneself, is becoming more prevalent among eating disorder patients. 

“Approximately 40 to 50 percent of our patients have either reported a history of self-injury or are presently engaging in these behaviors,” said Dena Cabrera, PsyD, psychologist and national speaker at Remuda Ranch. “This number seems to be consistent for the past five years. Studies have shown that adolescents engaging in self-injury behavior were more likely to have an eating disorder.”

Cutting may be increasing in our culture because young women today are struggling with identity issues and dealing with challenging problems. They feel they have to go to extremes to show others that they are suffering. Often, they are suffering from depression. In a visual culture, cutting may be a voice to get needs met. Self-injury may represent that struggle visually while physiologically and emotionally numbing the pain.

Based on studies and direct patient reports, Dr. Cabrera lists the following as additional reasons for self-injury:

• Stimulation: Escaping dissociative experience through an intentional gesture to feel one’s body, thereby using self-injury as a self-grounding technique.
• Emotional Release: Self-imposed when feeling guilt, shame, weakness, anger or punishment.
• Relaxation: A pleasure response to the warmth of the blood and to the physical sensation of pain.
• Distraction: Inducing dissociation or a trance-like state to avoid attending to an emotional trigger, issue, subject or suicidal thoughts.
• Social Attention: Obtaining self-affirmation by showing oneself and others one’s strength and achieving protection through the response of others.
• Alteration: Altering one’s body to make it unattractive to others through scarring.

At Remuda Ranch, Dialectical Behavior Therapy is used to teach patients skills to replace the self-harm behavior whether that behavior is an eating disorder, cutting, or both.

“We provide structure to the patient’s environment to motivate, reinforce and individualize appropriate skills needed for recovery,” adds Dr. Cabrera. “We also help remove negative behaviors as well as establish plans in case of relapse.”

“If someone you know is practicing self-injury it’s important to get help immediately,” said Dr. Cabrera. “Cutting is not like biting your nails, it can be very dangerous. Further, it perpetuates low self worth and esteem. It becomes a vicious cycle.”

About Remuda Ranch Programs for Eating and Anxiety Disorders
Remuda Ranch offers inpatient and residential programs for individuals of all faiths suffering from eating or anxiety disorders. Each patient is treated by a multi-disciplinary team including a psychiatric and a primary care provider, registered dietitian, master’s level therapist, psychologist and registered nurse. The professional staff equips each patient with the right tools to live a healthy, productive life. For more information, call
1-800-445-1900 or visit www.remudaranch.com.

Click here to see all recent news from this company

LEXINGTON, MA–(Marketwire – August 25, 2010) –  Imprivata^®, Inc., the company that simplifies and secures user access, today announced the formation of its Healthcare Advisory Board. This board draws upon real-world perspectives of industry leaders to address healthcare IT challenges and trends as the company develops innovative and practical solutions that solve the unique challenges facing the healthcare industry. Chaired by Barry P. Chaiken, MD, MPH, FHIMSS, chief medical officer of Imprivata, the Healthcare Advisory Board is comprised of Imprivata customers and industry experts, including:

• Michael Westcott, MD, CMIO, Alegent Health
• Denis Le Beuf, Chief Information Security Officer, Centre Hospitalier de l’Universite de Montreal
• Tarun Ghosh, CIO, Fremont-Rideout Health Group
• John Fernandez, CEO, Massachusetts Eye and Ear Infirmary
• Michael Krouse, Senior Vice President and CIO, OhioHealth
• Ted Lewis, President, Parkview Adventist Medical Center
• Deborah Peel, MD, Founder and Chair, Patient Privacy Rights

Through open sharing of experiences, dialogue about trends and regulatory influences and thoughtful debate, this new Healthcare Advisory Board is the latest example of Imprivata’s commitment to helping hospitals improve clinician workflow, enforce patient privacy and deploy transparent security.

“Today’s healthcare organizations face constant change, new regulatory mandates and a unique working environment that demands quick access to information but tight security on patient data,” said Dr. Michael Westcott, CMIO of Alegent Health, the largest healthcare system in Nebraska. The not-for-profit, faith based health care provider, which is 9,000 employees strong, has been an Imprivata customer since 2006. “One of the primary goals of the Healthcare Advisory Board is to share our experiences, study our similarities and differences, develop creative solutions to the challenges we face as an industry, and help Imprivata develop practical solutions that make a difference in hospitals around the world,” Dr. Westcott explained.

The Healthcare Advisory Board held its first meeting in Boston in June 2010 and will meet again in December. While topics for discussion at the first meeting were broad, there were clear commonalities among this varied group of healthcare organizations. Among the topics were:

• The impacts of the Healthcare Information Portability and Privacy (HIPAA) and Health Information Technology for Economic and Clinical Health (HITECH) Acts
• The role of access management in the implementation and “Meaningful Use” of EMRs
• Health information exchanges (HIEs) and the accompanying Beacon Grants (in ARRA)
• SSO and Strong Authentication enhancements for improved workflow
• Privacy and security
• Compliance demonstration, auditing and reporting
• Enterprise-wide business intelligence
• SaaS/cloud computing

“With the Healthcare Advisory Board, we have built a community of trusted, experienced and motivated members that are dedicated to triage industry priorities and provide fresh perspectives from C-level leaders,” said Barry P. Chaiken, MD, MPH, FHIMSS, chief medical officer of Imprivata. “I am very proud to be working with this diverse group of industry insiders and influencers to solve the problems of tomorrow — fast EMR access, patient privacy, security — today.”

Built upon a foundation of deep healthcare industry experience, Imprivata strives to make patient data easily accessible throughout clinical workflows, empowering physicians, nurses and other clinicians with fast EMR access, while enforcing stringent patient privacy policies through transparent security across healthcare information systems. Today Imprivatas’ Global Healthcare Division, has more than 550 healthcare customers and one million-plus healthcare users worldwide. 

“Imprivata long ago established a firm commitment to the healthcare industry, which has in turn fueled our rapid growth in recent years,” said Omar Hussain, president and CEO of Imprivata. “We have a history of not asking our customers what products they need, but rather spending time understanding what their problems and concerns are. It is in this mindset that we’re excited to tap into some of the healthcare industry’s brightest minds to spark vibrant discussion and help shape what solutions Imprivata brings to market over the long term.”

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers can align security with user workflows and realize substantial productivity gains while lowering IT costs.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews

Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

DALLAS, TX–(Marketwire – August 25, 2010) –  Metiscan, Inc. (PINKSHEETS: MTIZ), the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services, today announces results for its second quarter ending June 30, 2010. During the three months ended June 30, 2010, revenues were up 47% and cost of revenues were reduced 25% compared to the three months ended June 30, 2009. Additionally, for the first half of 2010, the Company had positive income from operations of $184,464 and would have had positive net income of approximately $140,000, if not for a one-time write-off of uncollectable notes of approximately $350,000 in the first quarter of 2010.

Interested parties may access MTIZ’s recent 10-Q from the SEC website at www.SEC.gov.

During the three months ended June 30, 2010 the Company’s revenues were $514,862 as compared to $349,423 during the three months ended June 30, 2009. This increase of $165,439, or 47%, is primarily the result of the Company’s operation of Schuylkill Open MRI, Inc. and FirstView EHR, Inc.

The Company’s cost of revenues during the three months ended June 30, 2010 were $140,333 as compared to $181,066 during the three months ended June 30, 2009. Cost of revenues as a percentage of revenues were 27% during the three months ended June 30, 2010 as compared to 52% during the three months ended June 30, 2009. This decrease of $40,733 or 25% is a result of the increased revenues with the Company’s change in operational focus.

During the six months ended June 30, 2010 the Company’s revenues were $1,413,490 as compared to $1,219,379 during the six months ended June 30, 2009, an increase of $194,111, or 16%. Additionally, for the first half of 2010, the Company demonstrated positive income from operations of $184,464 and would have had positive net income of approximately $140,000, if not for a one-time write-off of uncollectable notes of approximately $350,000 in Q1 of 2010.

Furthermore, during the second quarter ended June 30, 2010, 58,500,000 shares of common stock were issued of which 30,000,000 restricted shares were issued related to a settlement agreement, and 28,500,000 free trading shares were issued to Big Apple Equities, LLC for investor relations services. Therefore, the issuance of these shares increased the Company’s issued shares by approximately 2.5%.

As previously announced, Metiscan will be hosting a nationwide teleconference on Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) to update the financial community on points of interest that affect Metiscan and its shareholders. Space is limited on the call-in lines for this national teleconference, therefore in order to participate please call 407-389-5900 and ask for investor relations to make a reservation. If you have a particular question for the Company’s officers, please email questions in advance to [email protected].

About Metiscan, Inc.

Metiscan, Inc. (Metiscan) (PINKSHEETS: MTIZ) is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. 

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – August 25, 2010) –  WCG, a global communications company offering integrated creative, interactive and marketing communications services primarily to healthcare clients, today announced it won seven Awards of Excellence from the Communicator Awards, a leading international awards program honoring creative excellence in communications. The Award of Excellence is the highest honor in the competition, given to those entries that demonstrate “best in the field.”

The Communicator Awards are judged by the International Academy of the Visual Arts, a select and invitation-only group of leading professionals representing the best in media, communications, advertising, creative and marketing. Now in its 16th year, the awards competition had more than 9,000 entries from agencies of all sizes.

“This achievement is the result of our laser focus on putting creativity at the core of all we do so that we deliver the most impactful messaging — conceptually, visually and strategically,” said WCG’s Chief Creative Officer Paulo Simas. “I believe the strong combination of creative and strategy is foundational to a company’s success because creativity is innovation. And nothing catapults an organization like true innovation.”

WCG won the following Awards of Excellence:

• Perlegen — MammaPLUS ( logo)
• PEAK Surgical — PlasmaBlade ( packaging)
• Omnicell — ASHP Omnicell Apparel ( apparel)
• Viveve — Start the Conversation ( campaign)
• Elan — Elan Excellence ( pharmaceuticals)
• Medtronic — The 360 Suite ( biotechnology)
• Medtronic — Find the AAAnswers ( social responsibility)

About WCG

WCG is led by Chairman & CEO Jim Weiss, who was named to PRWeek’s Power List for 2010. The company also recently earned the distinction of North American Agency of the Year by the Holmes Report.

WCG’s mission is to create the positive future of communications by focusing on the corporate, product marketing and communications needs of the world’s leading companies.

Serving clients from offices in San Francisco, New York, Chicago, Washington, D.C., Austin and London, WCG’s seasoned professionals specialize in branding, design, digital, interactive, social and traditional marketing, corporate and product PR, media, investor and advocacy relations, clinical trial recruitment and grassroots direct-to-patient communications campaigns.

For more information, please visit www.wcgworld.com.